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Potential bone marrow donors are screened to ensure the safety of both the donor and recipient. At our
institution, potential donors with abnormal peripheral blood cell counts, a personal history of malignancy, or
age >60 years are evaluated to ensure that they are viable candidates for donation. Evaluation of the marrow
includes morphologic, ﬂow cytometric, and cytogenetic studies. A total of 122 potential donors were screened
between the years of 2001and 2011, encompassing approximately 10% of all donors. Of the screened potential
donors, the mean age was 59 years and there were 59 men and 63 women. The donors were screened
because of age >60 years (n ¼ 33), anemia (n ¼ 22), cytopenias other than anemia (n ¼ 27), elevated
peripheral blood counts without a concurrent cytopenia (n ¼ 20), elevated peripheral blood counts with
a concurrent cytopenia (n ¼ 10), history of malignancy (n ¼ 4), abnormal peripheral blood differential (n ¼ 3),
prior graft failure (n ¼ 1), history of treatment with chemotherapy (n ¼ 1), and body habitus (n ¼ 1). Marrow
abnormalities were detected in 9% (11 of 122) of donors. These donors were screened because of anemia (5 of
22, 23%), age >60 years (2 of 33, 6%), history of malignancy (2 of 4, 50%), elevated peripheral blood counts (1
of 20, 5%), and body habitus (1 of 1, 100%). Abnormalities included plasma cell dyscrasia (n ¼ 3), abnormal
marrow cellularity (n ¼ 3), clonal cytogenetic abnormalities (n ¼ 2), low-grade myelodysplastic syndrome (1),
a mutated JAK2 V617F allele (n ¼ 1), and monoclonal B cell lymphocytosis (n ¼ 1). Our experience indicates
that extended screening of potential donors identiﬁes a signiﬁcant number of donors with previously
undiagnosed marrow abnormalities.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION The transmission of disease from a BMT donor to recip-
Allogeneic blood or marrow transplantation (BMT) is the
deﬁnitive therapy for a variety of lymphoproliferative
disorders, leukemias, and other conditions affecting the bone
marrow, such as sickle cell anemia. Transplantation-related
mortality continues to decrease because of improvements
in immunosuppressive regimens and conditioning protocols,
as well as advances in HLA typing, and BMT is now a viable
therapy option for increasing numbers of patients. As a result
of these advances, the ages of both BMT recipients and
donors have increased [1].
The use of older bone marrow donors carries increased
risk for both the donor and recipient. The risks for older
donors include an increased likelihood of medical compli-
cations during the allograft collection and prolonged lym-
phopenias after hematopoietic stem cell donation [2]. Older
donors are also more likely to have underlying medical
conditions, which increase the risk of transmitting a disorder
from the donor to the recipient.edgments on page 1258.
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transmitted by BMT include genetic disorders, infections,
autoimmune diseases, and both hematologic and non-
hematologic malignancies [3-11]. Although once thought to
be a rare occurrence, “donor cell leukemia” is being reported
with increased frequency, with recent estimates suggesting it
may account for up to 5% of all leukemia “relapses” [12-18].
In addition, there are reports of lymphoma and myelodys-
plastic syndrome (MDS) that were transferred from donor to
recipient as a result of BMT [19-21]. The reasons for the
apparent recent increase in donor-derived malignancies
after allogeneic BMT are probably multifactorial and include
better recognition through modern molecular techniques, as
well as the use of older donors.
Although many medical disorders in donors are easily
identiﬁed through routine laboratory testing, some hema-
tologic disorders can be more challenging to identify, espe-
cially when peripheral blood counts remain within normal
limits. This is particularly true of low-grade or indolent
disorders, including plasma cell dyscrasia/monoclonal
gammopathy of undetermined signiﬁcance, monoclonal B
lymphocytosis (MBL), and lowgradeMDS. Although the risks
of these conditions developing into clinically signiﬁcant
disease after transplantation are not known, in most re-
ported cases of donor-recipient transmission of hematologic
malignancies, the donor abnormality was discovered when
the disease progressed and was diagnosed in the recipient.
Table 1
Donor Screening Results
Characteristic Donors Eliminated Donors Diagnosis
Totals 122 11 (9%)
Age, median (range), yr 59 (17-80) 62 (40-77)
Males 59 6 (10% of males)
Females 63 5 (8% of females)
Reason for evaluation
>60 yr old 33 2 (6%) Hypercellular marrow (n ¼ 1)
Abnormal karyotype (n ¼ 1)
Anemia 22 5 (23%) Plasma cell dyscrasia (n ¼ 2)
Low-grade myelodysplastic syndrome (n ¼ 1)
Hypocellular marrow (n ¼ 1)
Hypercellular marrow (n ¼ 1)
Elevated counts without concurrent cytopenia 20 1 (5%) Mutated JAK2 V617F
History of malignancy 4 2 (50%) Monoclonal B lymphocytosis (n ¼ 1)
Abnormal karyotype (n ¼ 1)
Body habitus 1 1 (100%) Plasma cell dyscrasia
Cytopenia(s) other than anemia 27 0
Elevated counts with concurrent cytopenia 10 0
Abnormal peripheral blood differential 3 0
Prior graft failure 1 0
History of treatment with chemotherapy 1 0
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screened with a comprehensivework-up to ensure the safety
of both the donor and the recipient. The screening includes
peripheral blood counts, physical examination, and a chest x-
ray. Potential donors with abnormal peripheral blood cell
counts, a personal history of malignancy, and those over
60 years of age undergo more comprehensive testing for
hematologic disorders, including a bonemarrow biopsy with
morphologic, ﬂow cytometric, molecular, and cytogenetic
analyses. From 2001 to 2011, 122 potential donors, repre-
senting approximately 10% of all donors, were evaluated
with a bone marrow aspirate and biopsy at our institution.
This study reviews the results of the extended screening of
these bone marrow donors. We ﬁnd that pathologic evalu-
ation of bone marrow allows the identiﬁcation of a signiﬁ-
cant population of donors with previously unrecognized
bone marrow abnormalities.
MATERIALS AND METHODS
Donor Identiﬁcation
The pathology database was searched using the keywords
marrow and donor, and 122 potential donors who were eval-
uated with a bone marrow aspirate and biopsy were identi-
ﬁed. Clinical datawere reviewed by one of the authors (A.S.D.)
in accordance with IRB-approved protocol NA_00051476.
Histology
Hematoxylin and eosin slides from formalin-ﬁxed and
parafﬁn-embedded bone marrow core biopsies were
reviewed along with Wright-Giemsaestained aspirate
smears. Any associated immunohistochemical stains per-
formed at the time of the original diagnosis were also
reviewed, but no additional stains were done solely for the
purposes of this study.
Flow Cytometry
Flow cytometric immunophenotyping was performed on
fresh bone marrow aspirates. The material was collected in
EDTA or heparin anticoagulant and processed routinely using
a red cell lysis method. Cell suspensions were incubated with
combinations of 4 monoclonal antibodies (Becton Dick-
inson,) that were used at concentrations titrated for optimal
staining. In most cases the panel included antibodies speciﬁcfor CD45, CD71, HLA-DR, CD33, CD13, CD2, CD3, CD5, CD7,
CD19, CD20, kappa light chain, lambda light chain, CD22,
CD10, CD34, CD56, CD38, CD14, CD64, CD61, CD11b, CD15,
CD117, and CD10, although occasional specimens were sub-
jected to an abbreviated panel. Selected antibody combina-
tions were conjugated to ﬂuorescein isothiocyanate,
phycoerythrin, peridinin chlorophyll protein, and allophy-
cocyanin ﬂuorochromes. Specimens were analyzed on a BDIS
FACSCalibur ﬂow cytometry system (Becton Dickinson
FACSCalibur, San Jose, California).
List mode data ﬁles were acquired and analyzed for each
specimen using CellQuest and Paint-a-Gate software
programs, respectively (Becton Dickinson). An antigen was
considered positive if the cells of interest either showed
a homogeneous distribution with the median intensity at
least 20 log channels above that seen in the control or if there
was a heterogeneous distribution of antigen expression, such
that a subpopulation of cells was above that seen in the
control. Cell populations were classiﬁed as dim, moderate,
and bright, based on their intensity compared with normal
counterpart cell populations. All ﬂow cytometric data were
reviewed by 2 of the authors (M.T. and A.S.D.).Cytogenetics
Cells from the bone marrow biopsies were cultured
without mitogens using current techniques and subse-
quently harvested. Slides were prepared and G-banded using
standard techniques. At least 20 metaphase cells were
analyzed per specimen.Fluorescence In-Situ Hybridization (FISH) Analysis
FISH analysis included probes 5p15.2 (D5S23, D5S23),
5q31 (EGR1), 7cen (D7Z1), 7q31 (D7S522), 8cen (D8Z2),
11q23 (MLL), and 20q12 (D20S108) (Abbott Molecular, Des
Plaines, Illinois). After FISH, 200 interphase nuclei were
scored for loci on 5p15.2, 5q31, 7 centromere, 7q31, 8
centromere, and 11q23. For 200 nuclei, the normal cutoffs
were as follows: <2.5% for monosomy 5, <3.5% for del(5q),
<4.4% for monosomy 7, <4.8% for del(7q), <6.7% for trisomy
8, and <3% for rearrangement of 11q23. Five hundred inter-
phase nuclei were scored for the locus on 20q12. For 500
nuclei, the normal cutoff for monosomy/del(20q) is <6%.
Table 2
Pathologic Findings in Abnormal Donors
Age, y/Sex Reason for Biopsy Marrow Morphology Flow Cytometry Cytogenetic/Molecular
Findings
Diagnosis Intended Recipient Outcome
62/F >60 yr of age Hypercellular (w60%) with increased
megakaryocytes, some of which are
small with hypolobated nuclei
N/D FISH: normal
Karyotype: normal
Underwent transplantation using another
family member as a donor
72/F >60 yr of age Mild hypercellularity (w60%) Normal FISH: normal
Karyotype: del(5q) [8/20]
Underwent transplantation using another
family member as a donor
72/M Anemia (HCT: 37.2%) Normocellular with <5% kappa light
chain-restricted plasma cells
N/D FISH: normal
Karyotype: N/D
Plasma cell dyscrasia Patient died of disease as potential donors
were being identiﬁed
77/F Anemia (HCT: 33.9%) Slightly hypercellular (40% to 50%) with
<10% monoclonal l-restricted plasma cells
4% l -restricted plasma cells FISH: normal
Karyotype: normal
Plasma cell dyscrasia No other potential donors identiﬁed;
autologous transplantation performed
43/F Anemia (HCT: 22.6%) Hypercellular (100%) with atypical
megakaryocytes & dysplastic myeloid
maturation
N/D FISH: normal
Karyotype: normal
Low-grade
myelodysplastic
syndrome
Transplantation cancelled because of disease
progression
72/M Anemia (HCT: 35.9%) Hypercellular (50% to 60%) with occasional
small megakaryocytes with hypolobated
nuclei
Normal FISH: normal
Karyotype: normal
Underwent transplantation using another
family member as a donor
46/M Anemia (HCT: 39.4%) Hypocellular (w20%) Normal FISH: normal
Karyotype: normal
Transplantation cancelled because of
disease progression
40/M Elevated platelets
(411 K/cu mm)
Normal Normal Mutated JAK2 V617F allele
FISH: normal
Karyotype: normal
Patient refused transplantation
71/M History of renal
cell carcinoma
Hypercellular (60% to 70%) with scattered
B lymphocytes
(2%) monoclonal B
lymphocytes (CD20-bright,
CD5-, CD10-, lþ)
FISH: normal
Karyotype: balanced
t(2;3), -Y
Monoclonal
B lymphocytosis
Transplantation on hold because of excellent
response to chemotherapy; partially
matched unrelated donor was identiﬁed
if needed
45/M History of testicular
cancer
Normal Normal FISH: del(20q) (10%)
Karyotype: del(20q) [3/21]
Underwent transplantation using another
family member as a donor
54/F Body habitus Normal Few CD56þ, k-restricted
plasma cells
FISH: normal
Karyotype: normal
Plasma cell dyscrasia Transplantation cancelled because of disease
progression
N/D indicates that the test was not done; HCT, hematocrit.
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The potential donors included 59 men and 63 women. The
median age of the screened potential donors was 59 (range,17
to 80) years. The indications for marrow evaluation in the
donors are summarized in Table 1 and include the following:
age > 60 years, anemia, elevated counts without a concurrent
cytopenia, history of malignancy, body habitus (obesity),
cytopenias other than anemia, elevated counts with
a concurrent cytopenia, abnormal peripheral blood differen-
tial, prior graft failure, and history of treatment with chemo-
therapy. Eleven (9%) of the potential donors who were
screened were rejected because of abnormalities found upon
pathologic examination of the marrow. The reasons for bone
marrow evaluation on these rejected donors included anemia
(n ¼ 5), history of malignancy (n ¼ 2), age > 60 years (n ¼ 2),
elevated peripheral blood counts (n ¼ 1), and body habitus
(n ¼ 1). Atypical ﬁndings in the 11 donors were detected by
morphologic examination of the marrow (n ¼ 5), ﬂow cyto-
metric studies (n¼ 1), both biopsy and ﬂowcytometry (n¼ 2),
molecular studies (n ¼ 1), cytogenetic studies (n ¼ 1), and
both biopsy and cytogenetic studies (n ¼ 1) (Table 2).
Thirty-three donors underwent extended screening
solely because they were over 60 years old, and 2 potential
donors (2 of 33, 6%) were eliminated. A 62-year-old woman
had hypercellular (60%) marrow for her age with increased
morphologically atypical megakaryocytes. Of note, there was
no evidence of dysplasia on the aspirate and cytogenetic
studies were normal. Another 72-year-old female donor also
showed slightly hypercellular marrow with nonspeciﬁc
changes on morphologic examination of the biopsy, but
a karyotype showed a clonal population of cells with del(5q).
Metaphase FISH with a probe mapped at 5q31 failed to show
the deletion as the probe is located outside the deleted
segment. Neither of these potential donors had cytopenias;
however, theywere excluded from the donor pool because of
concern for an evolving primary marrow disorder.
Five of 22 (23%) potential donors with anemia were found
to have bone marrow abnormalities. Two donors were diag-
nosed with plasma cell dyscrasia. Both donors had a relatively
mild anemia; a 72-year-old man had a hematocrit of 37.2%
(normal male range: 41% to 53%), and a 77-year-old woman
had a hematocrit of 33.9% (normal female range: 36% to 46%).
The diagnosis was identiﬁed by marrow biopsy in the male
donor, and by biopsy and ﬂow cytometric analysis in the
female donor’s marrow. A third potential donor was a 43-
year-old woman with a hematocrit of 22.6%. Morphologic
examination of the biopsy and aspirate showed a markedly
hypercellular marrow with atypical megakaryocytes and
dysplastic myeloid maturation, consistent with a low-grade
myelodysplastic syndrome. Cytogenetic studies were normal
in this potential donor. The remaining 2 donors with anemia
were excluded because of marrow abnormalities, although
the ﬁndings were not diagnostic of a speciﬁc primary marrow
disorder. Both of these donors were men with only a mild
decrease in hematocrit. A 72-year-old potential donor with
a hematocrit of 35.9% had abnormally hypercellular (50% to
60%) marrow on biopsy, and a 46-year-old potential donor
had abnormally hypocellular (about 20%) marrow.
Twenty potential donors had elevated peripheral blood
counts with no concurrent cytopenia, and 1 (1 of 20, 5%) of
these donors was found to have a marrow abnormality. This
healthy 40-year-old man had normal peripheral blood
counts with the exception of a slightly elevated platelet
count (411 K/cumm, normal range: 150 K/cumm to 350 K/cu
mm). Morphologic, ﬂow cytometric, and cytogenetic studieswere normal, but molecular testing demonstrated the pres-
ence of at least 1 mutated JAK2 V617F allele.
Four donors were evaluated because of a history of
malignancy; the potential donors had a history of prostate
cancer, breast cancer, testicular cancer, and renal cell carci-
noma. Two (2 of 4, 50%) potential donors were eliminated
because of marrow ﬁndings. A 45-year-old man with
a history of testicular cancer who was treated with chemo-
therapy was found to have a clonal population of cells that
showed a deletion of chromosome 20q by FISH and meta-
phase analysis. The second eliminated donor was a 71-year-
old man with a history of renal cell carcinoma, although the
details of his treatment for renal cell carcinoma are
unknown. His bone marrow was hypercellular. An immu-
nostain for CD20 showed scattered B cells, and ﬂow cytom-
etry studies demonstrated a small population of monoclonal
lymphocytes that expressed bright CD20 and were negative
for CD5 consistent with a monoclonal B lymphocytosis.
Finally, 1 potential donor, an obese 54-year-old woman,
was found to have abnormalities on ﬂow cytometric analysis
of the marrow. This donor had normal blood counts and an
unremarkable medical history, and a bone marrow biopsy
was performed to determine whether a bone marrow
harvest was anatomically feasible. Although themorphologic
and cytogenetic studies were normal, ﬂow cytometric anal-
ysis demonstrated a small population of plasma cells that
expressed kappa light chain and aberrant CD56, consistent
with a plasma cell dyscrasia.
None of the potential donors who underwent extended
marrow evaluation due to cytopenias other than anemia (n¼
27), elevated counts with a concurrent cytopenia (n ¼ 10),
abnormal peripheral blood differential (n ¼ 3), prior graft
failure (n ¼ 1), and history of treatment with chemotherapy
(n ¼ 1) demonstrated marrow abnormalities.
Four of the potential donors with peripheral blood count
abnormalities had normal ﬁndings on the marrow studies
but were eliminated from consideration because of other
reasons. Chest x-rays revealed adenocarcinoma in the lung in
a 61-year-old man with anemia, as well as a mediastinal
mass in a 38-year-old man with lymphopenia. A 63-year-old
manwith anemiawas eliminated because he had blood in his
stool, raising concern for a potential gastrointestinal malig-
nancy. Finally, a 21-year-old man with elevated hemoglobin
and a mild leukopenia was found to have HLA antibodies
against the potential recipient.
DISCUSSION
Thorough and effective pretransplantation screening of
potential allogeneic bone marrow donors is essential to
ensure the best outcome for both the donor and the recip-
ient. Pretransplantation donor screening procedures are not
standardized, but elements of the work-up are common to
most institutions, including a thorough medical history and
physical examination, laboratory studies with a complete
blood count and blood chemistries, testing for transmissible
diseases, an electrocardiogram, and chest x-ray. Sampling
and examination of a potential donor’s bone marrow is often
not routinely performed.
At our institution, we began performing bone marrow
evaluation, including morphology, cytogenetics, and ﬂow
cytometry, on potential donors who were over 60 years old
and had abnormal peripheral blood counts or a personal
history of malignancy. In this study we evaluated the results
of screening these donors over the past 10 years. We found
that 11 of 122 (9%) of donors had hematologic abnormalities
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and as a result of these ﬁndings we have begun routinely
testing all potential donors who meet the aforementioned
criteria.
Most of the donors in whom abnormalities were found
either had a prior disease history or evidence of peripheral
blood count abnormalities; features that most would accept,
warrant more extensive investigation. However, 2 of 33
donors screened based on age alone also had marrow ﬁnd-
ings that precluded their donating. Although our institution
utilizes 60 years of age as a cut-off for extended screening,
other authors have suggested that donors over 55 years old
should be screened [1]. These limits are relatively arbitrary,
and the potential for even younger donors to have an
undetected marrow abnormality is demonstrated by the
plasma cell dyscrasia that was identiﬁed in a 54-year-old
potential donor with normal peripheral blood counts who
was evaluated because of her body habitus. Although unex-
pected marrow abnormalities can be found even in younger
donors with an unremarkable medical history, current data
are limited and, at this time, it is not possible to determine
the optimal age to begin routine extended screening.
The marrow evaluations performed in this study tended
to identify relatively minor abnormalities. Of the 11 donors
who were rejected, only 4 were given a deﬁnitive diagnosis
of a hematologic abnormality including plasma cell dyscrasia
(n ¼ 3), MBL (n ¼ 1), and low-grade MDS (n ¼ 1). The
remaining donors were rejected because of either morpho-
logic abnormalities in the marrow including hypercellularity
(n ¼ 2) or hypocellularity (n ¼ 1), a JAK V617F mutation
(n¼ 1), or clonal cytogenetic abnormalities that did not meet
the criteria for a diagnosis of MDS (n¼ 2). Although in theory
rejecting these donors can potentially beneﬁt the recipient
by reducing the possibility of a donor transmitted neoplasm,
in practice, the risks of transmitting such a neoplasm are
largely unknown. Plasma cell dyscrasia and MBL, in partic-
ular, rarely progress to overt malignancy, although it is not
clear what effects the stress of hematologic reconstitution
could have on these conditions [22]. Moreover, ﬁnding
unexpected abnormalities can trigger anxiety in the poten-
tial donor who now requires monitoring for laboratory
ﬁndings that may never evolve into a full-ﬂedged neoplasm.
Other potential disadvantages of marrow evaluation in the
screening of potential bone marrow donors include
increased cost, possible morbidity, and increased reluctance
of candidates to undergo the screening process [23]. For all
these reasons, extensive donor screening should be under-
taken carefully, and decisions about what to do with the
results must be made in context of individual patient
circumstances [24].
One possible concern is that screening could eliminate
the only available donor for a patient. One patient in this
study did not undergo a BMT because his donor was elimi-
nated, and the patient ultimately died. Of note, this donor
was eliminated in 2001, and a similar outcome would be
unlikely today. Recent advances now demonstrate that
unrelated cord blood and haploidentical related trans-
plantation are able to produce results similar to matched
sibling BMT; thus, most patients should now have multiple
acceptable donor options [25]. In this study, 1 recipient
received an autologous transplant and all other potential
recipients who desired or remained eligible for trans-
plantation had an alternative donor identiﬁed (Table 2).
These data demonstrate that pathologic evaluation of the
marrow with morphologic, ﬂow cytometric, molecular, andcytogenetic studies identiﬁes a signiﬁcant number of
marrow abnormalities in selected potential donors. The
recent success of alternative donor transplantations would
appear to make screening potential donors to rule out
transplantable diseases even more important, and adopting
this extended screening strategy may help to optimize
patient outcomes in BMT.ACKNOWLEDGMENTS
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Patients with class 3 thalassemia with high-risk features for adverse events after high-dose chemotherapy with
hematopoietic stem cell transplantation (HSCT) are difﬁcult to treat, tending to either suffer serious toxicity or
fail to establish stable graft function. We performed HSCT in 18 such patients age 7 years and hepatomegaly
using a novel approach with pretransplant immunosuppression followed by a myeloablative reduced-toxicity
conditioning regimen (ﬂudarabine and i.v. busulfan [Flu-IV Bu]) and then HSCT. The median patient age was
14 years (range, 10 to 18 years). Before the Flu-IV Bu þ antithymocyte globulin conditioning regimen, all
patients received 1 to 2 cycles of pretransplant immunosuppression with ﬂudarabine and dexamethasone.
Thirteen patients received a related donor graft, and 5 received an unrelated donor graft. An initial prompt
engraftment of donor cells with full donor chimerism was observed in all 18 patients, but 2 patients developed
secondary mixed chimerism that necessitated withdrawal of immunosuppression to achieve full donor
chimerism. Two patients (11%) had acute grade III-IV graft-versus-host disease, and 5 patients had limited
chronic graft-versus-host disease. The only treatment-related mortality was from infection, and with a median
follow-up of 42 months (range, 4 to 75), the 5-year overall survival and thalassemia-free survival were 89%. We
conclude that this novel sequential immunoablative pretransplantation conditioning program is safe and
effective for patients with high-risk class 3 thalassemia exhibiting additional comorbidities.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the sole available curative therapy for patients with
severe b-thalassemia, providing potential cure in approxi-
mately 80% of recipients [1]. However, several reports have
suggested the existence of a subset of patients with worse
outcomes. This subgroup includes older patients with
normal organ damage due to iron overload and/or evidence
of immunization to donor histocompatibility antigens
